

FIRM / AFFILIATE OFFICES

Barcelona	New Jersey
Brussels	New York
Chicago	Northern Virginia
Frankfurt	Orange County
Hamburg	Paris
Hong Kong	San Diego
London	San Francisco
Los Angeles	Shanghai
Madrid	Silicon Valley
Milan	Singapore
Moscow	Tokyo
Munich	Washington, D.C.

**LATHAM & WATKINS** LLP

May 30, 2008

**VIA EDGAR**

Michael Reedich, Esq.  
Special Counsel  
Office of Health Care and Insurance  
Division of Corporation Finance  
Securities and Exchange Commission  
100 F Street, N.E.  
Washington, D.C. 20549

Re: Corcept Therapeutics Incorporated  
Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-150232)  
Filed May 30, 2008

Dear Mr. Reedich:

On behalf of our client Corcept Therapeutics Incorporated (the "Company" or "Corcept"), pursuant to Rule 477 of the Securities Act of 1933, as amended (the "Securities Act"), the Company hereby respectfully requests acceleration pursuant to Rule 461 under the Securities Act of 1933, as amended, of the Registration Statement on Form S-1 (Registration No. 333-150232) of the Company, original filed on April 14, 2008 and as amended by Amendment No. 1 thereto filed on May 30, 2008 (as amended, the "Registration Statement"), so that the Registration Statement will be declared effective by the Securities and Exchange Commission (the "Commission") at 4:00 p.m. EDT on June 3, 2008, or as soon as practicable thereafter.

In connection with the foregoing request for acceleration of such Registration Statement, the Company has authorized us to acknowledge on its behalf that:

- should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
- the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

- the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Please call the undersigned at (202) 267-2242 if you wish to discuss this request.

Very truly yours,

/s/ John J. Huber

John J. Huber

of LATHAM & WATKINS LLP

cc: Song P. Brandon, Esq., Securities and Exchange Commission  
Joseph K. Belanoff, Corcept Therapeutics Incorporated  
Alan C. Mendelson, Latham & Watkins LLP  
Keith Benson, Latham & Watkins LLP